Harrow Announces Third Quarter 2025 Financial Results

Core Insights - Harrow reported a significant revenue increase of 45%, reaching $71.6 million in Q3 2025 compared to $49.3 million in the same period last year [7][10] - The company achieved a GAAP net income of $1.0 million, a notable improvement from a net loss of $4.2 million in Q3 2024 [10][21] - Adjusted EBITDA for the quarter was $22.7 million, up from $8.8 million in the prior year [7][26] Business Highlights - The launch of TRIESENCE® into its largest market opportunity and the rollout of the Harrow Access for All (HAFA) program are key strategic initiatives aimed at future growth [5][9] - Harrow's cash and cash equivalents stood at $74.3 million as of September 30, 2025, compared to $47.2 million at the end of 2024 [7][19] - The company entered into an agreement to acquire Melt Pharmaceuticals, which focuses on non-opioid sedation therapies, potentially transforming patient experiences in medical procedures [8] Coverage Expansion - Harrow secured coverage agreements with major national payers, enhancing the accessibility of VEVYE® with preferred product status expected to take effect on January 1, 2026 [14] - A partnership with Alto Pharmacy powered by Fuze Health was established to expand the VEVYE Access For All (VAFA) program, improving patient access and affordability [14]